Pharmacoepidemiology: Lessons from real life

Joint Bone Spine

Volumn 71, Issue 3, 2004, Pages 175-177

  Fautrel, B ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Coxib; Nonsteroidal antiinflammatory drugs; Pharmacoepidemiology

Indexed keywords

BENZODIAZEPINE; CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PROTON PUMP INHIBITOR; ROFECOXIB; THALIDOMIDE; TRYPTOPHAN;

BIRTH DEFECT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; EOSINOPHILIA; GASTROINTESTINAL SYMPTOM; HEALTH CARE SYSTEM; HEALTH INSURANCE; HEART INFARCTION; HUMAN; INJURY; LUNG EDEMA; METHODOLOGY; MYALGIA; NEPHROTOXICITY; PHARMACODYNAMICS; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; THROMBOEMBOLISM; TRAFFIC ACCIDENT;

CYCLOOXYGENASE INHIBITORS; GASTROINTESTINAL TRACT; HUMANS; PHARMACOEPIDEMIOLOGY; PROTON PUMPS;

EID: 2942516117     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2003.07.008     Document Type: Editorial

References (27)

1. FitzGerald G.A., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 345:2001;433-442
2. Deeks J.J., Smith L.A., Bradley M.D. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ. 325:2002;619
3. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 343:2000;1520-1528. VIGOR Study Group
4. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 284:2000;1247-1255
5. Strom B.L. What is pharmacoepidemiology? 3rd ed Strom B.L. Pharmacoepidemiology. 2000;3-15 John Wiley & Sons, Ltd, Chichester (UK)
6. Lenz W. Malformations caused by drugs in pregnancy. Am J Dis Child. 112:1966;99-106
7. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet. 346:1995;1575-1582
8. Eidson M., Philen R.M., Sewell C.M., Voorhees R., Kilbourne E.M. L-tryptophan and eosinophilia-myalgia syndrome in New Mexico. Lancet. 335:1990;645-648
9. Werner-Felmayer G., Werner E.R., Weiss G., Wachter H. Peak E contaminated L-tryptophan and immune activation. Lancet. 338:1991;511
10. Abenhaim L., Moride Y., Brenot F., Rich S., Benichou J., Kurz X., et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. 335:1996;609-616
11. Barbone F., McMahon A.D., Davey P.G., Morris A.D., Reid I.C., McDevitt D.G., et al. Association of road-traffic accidents with benzodiazepine use. Lancet. 352:1998;1331-1336
12. Tamblyn R., Laprise R., Hanley J.A., Abrahamowicz M., Scott S., Mayo N., et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 285:2001;421-429
13. Walley T., Mantgani A. The UK general practice research database. Lancet. 350:1997;1097-1099
14. Jick H. A database worth saving. Lancet. 350:1997;1045-1046
15. Rahme E., Marentette M.A., Kong S.X., LeLorier J. Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population. Arthritis Rheum. 47:2002;595-602
16. Collet J.P., Boivin J.F. Bias and confounding in pharmacoepidemiology. 3rd ed Strom B.L. Pharmacoepidemiology. 2000;765-784 John Wiley & Sons, Chichester (UK)
17. Mamdani M., Rochon P.A., Juurlink D.N., Kopp A., Anderson G.M., Naglie G., et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ. 325:2002;624
18. Laine L., Connors L.G., Reicin A., Hawkey C.J., Burgos-Vargas R., Schnitzer T.J., et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology. 124:2003;288-292
19. Mukherjee D., Nissen S.E., Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 286:2001;954-959
20. Solomon D.H., Avorn J. Pharmacoepidemiology and rheumatic diseases: 2001-2002. Curr Opin Rheumatol. 15:2003;122-126
21. Dalen J.E. Selective COX-2 inhibitors, NSAIDs, aspirin, and myocardial infarction. Arch Intern Med. 162:2002;1091-1092
22. Solomon D.H., Glynn R.J., Levin R., Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med. 162:2002;1099-1104
23. Rahme E., Pilote L., LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med. 162:2002;1111-1115
24. Watson D.J., Rhodes T., Cai B., Guess H.A. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med. 162:2002;1105-1110
25. Baigent C., Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. Arthritis Rheum. 48:2003;12-20
26. Feenstra J., Heerdink E.R., Grobbee D.E., Stricker B.H. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Arch Intern Med. 162:2002;265-270
27. Bouee S., Charlemagne A., Fagnani F., Le Jeunne P., Sermet C., Naudin F., et al. Changes in osteoarthritis management by general practitioners in the COX2-inhibitor Era-concomitant gastroprotective therapy. Joint Bone Spine. 70:2003;. (this issue)